|
By Staff of The Life Sciences Report
|
|
Wednesday, 15 July 2015 14:46 |
 In the U.S., the medical device and diagnostics industry has been burdened with conflicting regulations that have delayed commercialization and complicated reimbursement.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 24 June 2015 14:45 |
 Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 17 June 2015 18:06 |
 The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 10 June 2015 19:16 |
|
Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: artificial sweeteners, blood tests, sleep aids, cancer treatments, brain health.
|
|
Read more...
|
|
By William Kent
|
|
Wednesday, 03 June 2015 12:57 |
 Chen Lin produces a monthly scorecard that tracks the performance of the stocks in which he invests. Every month, he reveals how he is doing in his newsletter, What Is Chen Buying? What is Chen Selling?
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 27 May 2015 18:43 |
|
Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 20 May 2015 15:16 |
|
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of the stocks he writes about. In this interview with The Life Sciences Report, Silver puts two biotech names on the table for investors to consider.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Wednesday, 13 May 2015 18:23 |
 An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Thursday, 07 May 2015 15:20 |
 Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments.
|
|
Read more...
|
|
By George S. Mack of The Life Sciences Report
|
|
Thursday, 23 April 2015 12:38 |
|
There's a new kind of incubator in town. The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian nonprofit that fosters hands-on association between academia, government, industry and investors to grow stem cell and regenerative medicine companies from the ground up. In this interview with The Life Sciences Report,
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 6 of 56 |
